PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors ; volume:23 ; number:1 ; day:21 ; month:1 ; year:2021 ; pages:1-17 ; date:12.2021
Breast cancer research ; 23, Heft 1 (21.1.2021), 1-17, 12.2021
- Urheber
-
Bai, Feng
Liu, Shiqin
Liu, Xiong
Hollern, Daniel P.
Scott, Alexandria
Wang, Chuying
Zhang, Lihan
Fan, Cheng
Fu, Li
Perou, Charles M.
Zhu, Wei-Guo
Pei, Xin-Hai
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-021-01387-x
- URN
-
urn:nbn:de:101:1-2021042021290048316541
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bai, Feng
- Liu, Shiqin
- Liu, Xiong
- Hollern, Daniel P.
- Scott, Alexandria
- Wang, Chuying
- Zhang, Lihan
- Fan, Cheng
- Fu, Li
- Perou, Charles M.
- Zhu, Wei-Guo
- Pei, Xin-Hai
- SpringerLink (Online service)
Ähnliche Objekte (12)
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
BRCA1 deficient mammary tumors are dependent on EZH2 expression and sensitive to polycomp repressive complex 2-inhibitor 3-deazaneplanocin A
BRCA1 mutation influences progesterone response in human benign mammary organoids
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
Mammary gland transgenesis: therapeutic protein production
BRCA1 Deficiency: BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis (Adv. Sci. 6/2020)
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1
BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Keratin 6 is not essential for mammary gland development
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
BRCA1 deficient mammary tumors are dependent on EZH2 expression and sensitive to polycomp repressive complex 2-inhibitor 3-deazaneplanocin A
BRCA1 mutation influences progesterone response in human benign mammary organoids
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
Mammary gland transgenesis: therapeutic protein production
BRCA1 Deficiency: BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis (Adv. Sci. 6/2020)
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1
BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Keratin 6 is not essential for mammary gland development
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
BRCA1 deficient mammary tumors are dependent on EZH2 expression and sensitive to polycomp repressive complex 2-inhibitor 3-deazaneplanocin A
BRCA1 mutation influences progesterone response in human benign mammary organoids
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
Mammary gland transgenesis: therapeutic protein production
BRCA1 Deficiency: BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis (Adv. Sci. 6/2020)
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1
BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression